Monday May 13
Marina Biotech, Inc. Announces That Licensee Mirna Therapeutics, Inc. ...
Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer.
Covagen Names Elias Papatheodorou Chief Business Officer
He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.
Atossa Genetics - Will Investors Be Holding The Bag?
Atossa Genetics has had a huge run up. It went from $6.93 on March 13, 2013 to $11.30 at the time of this writing.
Bothell biotech companies advanced biopharmaceutical products featured in new report
America's biopharmaceutical companies, including three in Bothell, are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America .
Moving Towards Earlier, Better Diagnosis of Breast Cancer: Interview...
Breast cancer is diagnosed in over 200,000 women annually in the US, according to the CDC.